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ORIGINAL ARTICLE
Prospective study of human herpesvirus 8 oral shedding, viremia, and
serological status among human immunodeficiency virus seropositive and
seronegative individuals in Sao Paulo, Brazil
Paulo H. Braz-Silva a,b, Tania R. Tozetto-mendozaa, Laura M. Sumitaa, Wilton Freirea, Michelle Palmierib,
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ABSTRACT
Human herpesvirus 8 (HHV-8) is a gamma-herpesvirus and etiological agent of all forms of
Kaposi sarcoma (KS). Saliva may play an important role in HHV-8 transmission in specific
populations. Little is known about HHV-8 oral shedding pattern and the possible correlation
with the HHV-8 serological profile and viremia. A prospective study was conducted of HHV-8
salivary excretion among human immunodeficiency virus HIV-seronegative (n = 47) and
-seropositive (n = 44) homosexual men and HIV-seropositive women (n = 32) over a 6-
month period with monthly HHV-8 serologies (immunofluorescence assays to identify anti-
bodies to latent and lytic HHV-8 viral proteins, and a whole-virus HHV-8 enzyme-linked
immunosorbent assay [ELISA]), monthly HHV-8 DNA serum/plasma detection, and daily self-
collected oral rinses for HHV-8-DNA detection using real-time polymerase chain reaction.
HHV-8 seropositivity was 51.1%, 63.6%, and 37.5%, in the three studied groups. There was no
case of HHV-8 DNA detection in serum/plasma. Intermittent detection of oral HHV-8 DNA was
observed during 5.1% (110/2,160) of visits among 28% (18/64) of HHV-8-seropositive indivi-
duals, all of whom were males and HHV-8 ELISA seropositive. In immunologically controlled
populations of Brazil, HHV-8 oral shedding was limited to HHV-8-seropositive men, occurred
infrequently and intermittently, and was not linked to HHV-8 viremia, suggesting a limited
potential for oral or blood transmission.
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Introduction
Transmission of human herpesvirus 8 (HHV-8), the
agent of Kaposi sarcoma (KS) and other human
immunodeficiency virus (HIV)-associated rare con-
ditions, has been the subject of conflicting evidence
[1]. Oral samples have been consistently shown to
have the highest rates of HHV-8 viral detection com-
pared to semen, urine, urethral, vaginal, and anal
samples, suggesting that saliva may play an important
role in HHV-8 transmission [2–9]. On the other
hand, transmission through blood and blood transfu-
sion remains a controversial issue with no conclusive
evidence [10–12]. Studies among blood donors out-
side KS endemic areas have shown very rare detection
of HHV-8 DNA in blood samples, even among
HHV-8-seropositive individuals [10,11].
Associations between HHV-8 serological status
and HHV-8 DNA oral shedding are also not clear,
with some studies even showing HHV-8 oral shed-
ding in HHV-8-seronegative individuals [13]. The
lack of a gold standard for HHV-8 serological status
further compounds the limited ability to determine
‘true infection’ status [14].
This study aimed to assess prospectively the fre-
quency of HHV-8 detection in saliva, serum, and
plasma and their association with HHV-8 serological
status among HIV-seronegative and -seropositive
men who have sex with men (MSM) and HIV-sero-
positive women—groups that have a high probability
of being infected with HHV-8.
Methods
Study participants and sample collection
A convenience sample of individuals were included
from three groups: HIV-seronegative MSM, HIV-
seropositive MSM, and HIV-seropositive women.
Volunteer patients either self-presenting or referred
by the STD Training Center/AIDS-SP in Sao Paulo
for dental care were consecutively recruited at the
Dental Special Care Center of the School of
Dentistry, University of Sao Paulo, Brazil, where
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the purpose and procedures of the study were
explained. The patients had no history of KS or
other lesions associated with HHV-8. All patients
signing informed consent were invited to a prospec-
tive follow-up over a 6-month period consisting of
two sequential 3-month periods separated by
60 days, with biweekly appointments at the dental
clinic where patients would bring their daily
(Monday to Friday) self-collected mouthwashes.
Self-collection commercial oral rinse kits
(Listerine®, Johnson & Johnson, Sao Paulo, Brazil)
were distributed to each patient, consisting of
50 mL plastic tubes (pre-labeled for the collection
day) and a bottle of Listerine®. All participants were
instructed to use 5 mL of the moutwash solution
for 1 min at night and to collect all the contents of
the oral rinse in the tube. Samples were stored in
patients’ homes in a refrigerator at 4°C until the
next dental appointment. The aim was to collect a
total of 120 oral rinses from each patient. If a
patient had not submitted this number, the collec-
tion period was extended up to 4 weeks (2 weeks in
each period of 3 months) to attain that number. In
addition, blood samples were drawn at the study
entry and at monthly appointments. All samples
were stored at −80°C until testing.
Serological assays
Six serum samples from each patient were tested
without knowledge of other results in a random
patient and samples order for HHV-8 serologies at
the Laboratory of Virology, Institute of Tropical
Medicine, University of Sao Paulo, using in-house
immunofluorescence assays (IFA) to identify antibo-
dies to latent and lytic HHV-8 viral proteins, and a
whole-virus HHV-8 enzyme-linked immunosorbent
assay (ELISA) for immunoglobulin G detection, as
described previously [14].
HHV-8 molecular assays
DNA extraction
DNA was extracted from oral rinse, serum, and
plasma samples (200 μL) using a NucliSENS®
easyMAG® (bioMerieux, Durham, NC), an IVD-
labeled automated system for total nucleic acid
extraction based on magnetic silica technology,
according to the manufacturer’s instructions. DNA
concentration was mesured by spectrophotometry at
260 nM in a NanoDrop™ (Thermo Fisher Scientific,
Waltham, MA). Beta-actin DNA was also detected in
all samples by using real-time polymerase chain reac-
tion (PCR), according to the manufacturer’s protocol
(Taq Man DNA Template Reagents Kit; Applied
Biosystems, Foster City, CA), in order to evaluate
the viability of the DNA isolated from each sample.
ORF 26 real-time PCR.
Oral rinses, serum, and plasma samples were analysed
in triplicate for HHV-8 DNA detection and quantifica-
tion using real-time PCR, as described [11]. Quantities
of HHV-8 DNA were log10 transformed to normalize
values for analysis. Samples with ≥5 copies/mL (0.7
log10) were considered positive.
Statistical analyses
The proportions of patients and days with detectable
HHV-8 DNA in oral rinse, serum, and plasma sam-
ples were compared across the groups and by serolo-
gical assay using chi-square statistics. For the
quantitative analysis of viral shedding, the median
values of HHV-8 DNA were compared among sam-
ples with detectable HHV-8 using the Kruskal–Wallis
and Wilcoxon rank-sum tests. Inter-assay (serology)
concordance (overall, positive, and negative agree-
ments) was calculated using simple proportions.
Performance of serological assays to detect HHV-8
shedding was calculated using standard 2 × 2 tables,
and results are given with their 95% confidence inter-
vals (CI). Data were analysed using Stata v14 (Stata
Corp., College Station, TX).
Results
Overall, 123 individuals (47 HIV-seronegative MSM,
44 HIV-seropositive MSM, and 32 HIV-seropositive
women) were enrolled in this study from March to
May 2013, and they were followed up for a 6-month
period. Participants’ characteristics are shown in
Table 1. All HIV-seropositive individuals were taking
highly active antiretroviral therapy (HAART), and
around 80% had undetectable HIV plasma viral loads
(threshold for detection: 50 copies/mL) and high
CD4 + T-lymphocyte counts (68.1% of men and
75.0% of women with CD4+ count ≥500 cells/mm3)
at enrolment.
At the end of the study period, all patients had
produced 120 self-collected oral samples, six serum
samples, and six plasma samples. Forty-two (34.1%)
patients needed an extended period to collect the oral
rinses (ranging from 3 to 20 samples for a range of 1
to 4 weeks).
Overall, 24/47 (51.1%) HIV-seronegative MSM,
28/44 (63.6%) HIV-seropositive MSM, and 12/32
(37.5%) HIV-seropositive women were positive by
at least one HHV-8 serological assay over six time
points (Table 1). Considering each assay separately,
there was a higher positivity by ELISA (48/123;
39.0%), followed by IFA-LANA (33/123; 26.8%),
and IFA-lytic (22/123; 17.9%).
The overall intra-assay concordance in 738 serum
samples was 100% (738/738) for ELISA, 99.2% 732/
738) for IFA-LANA, and 98.9% (730/738) for IFA-lytic,
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showing excellent reproducibility for all tests. Patients
with discordant intra-assay results were arbitrarily con-
sidered positive because themajority (4/6) of their serum
samples were positive. The intra-assay concordance for
negative results was 100% for each assay (Table 2).
HHV-8 DNA was not detected in any of the 738
serum or plasma samples after triplicate PCR testing.
HHV-8 DNA was not detected in any oral samples of
the 59 HHV-8-seronegative individuals (total 7,080
samples tested), but it was detected in 18/64 (28%)
HHV-8-seropositive individuals: 7/24 (29.2%) HIV-
seronegative MSM and 11/28 (39.3%) HIV-seroposi-
tive MSM (Table 1). The frequency of HHV-8 DNA
detection in samples from shedders was 5.1% (110/
2160) overall, 4.8% (40/840) in samples from HIV-
seronegative MSM, and 5.3% (70/1320) in samples
from HIV-seropositive MSM (p = 0.58), with a
range of positive samples between 3/120 (2.5%) and
11/120 (9.2%) per patient. The median quantity of
HHV-8 DNA detected among shedders was signifi-
cantly higher among the HIV-seropositive compared
to HIV-seronegative MSM (3.7 vs. 2.8 log10 copies/
mL, p < 0.01; Table 1).
The HHV-8 serological profile and the perfor-
mance of individual and combination serological
assays to detect HHV-8 shedders among the 91 men
is shown in Table 3. The evaluation did not include
women, since none had any demonstrable shedding.
The whole-virus ELISA had the highest sensitivity
(100.0%; 95% CI 81.5–100.0), lowest specificity
(67.1%; 95% CI 55.1–77.7), but high negative predic-
tive value (NPV; 100.0%; 95% CI: 92.7–100.0). The
best combination of assays was ELISA plus IFA-
LANA for its high specificity (91.8%; 95% CI 83.0–
96.9) without much loss of sensitivity (83.3%; 95% CI
58.6–96.4) and high positive predictive value (PPV;
71.4%; 95% CI 47.8–88.7; Table 3).
Discussion
In these high-risk populations, 29% of HHV-8/HIV
dually seropositive MSM, as well as 39% of HHV-8-
seropositive/HIV-seronegative MSM, were shedding
HHV-8 DNA at least once over a 6-month period,
while none of the HHV-8/HIV dually seropositve
women shed HHV-8. Among MSM, the frequency
of oral shedding was low (around 5% of days), irre-
spective of HIV serostatus, despite the large number
of samples (120) tested per individual. However, the
median quantity of oral HHV-8 DNA during epi-
sodes was significantly higher among HIV-seroposi-
tive shedders. Compared to other serological assays,
ELISA would be the best test to identify HHV-8
shedders, as it combines the highest NPV (no shed-
ding detected among ELISA-seronegative individuals)
and the highest sensitivity. The pattern of HHV-8
Table 1. Participants’ characteristics and HHV-8 antibody and DNA detection among HIV-positive and HIV-negative patients in
Sao Paulo, Brazil.
Male HIV negative,
N = 47
Male HIV positive,
N = 44
Female HIV positive,
N = 32 p-Value
Characteristics
Age (years), median (interquartile range) 30 (26–37) 40 (35–45) 42 (39–52) <0.01a
Proportion with CD4+ >500 cells/mm3 (%) n/a 30 (68.1) 24 (75.0) 0.52
Proportion with undetectable HIV PVL (%)b n/a 35 (79.5) 27 (84.3) 0.59
HHV-8 serology positivity
ELISA (%) 18 (38.3) 24 (54.6) 6 (18.8) <0.01c
IFA-LANA (%) 14 (29.8) 13 (29.6) 6 (18.8) 0.49
IFA-lytic (%) 8 (17.0) 10 (22.7) 4 (12.5) 0.51
Any assay (%) 24 (51.0) 28 (63.6) 12 (37.5) 0.08
HHV-8 DNA detection among all patients N = 47 N = 44 N = 32
Serumd 0 0 0 —
Plasmad 0 0 0 —
Saliva (per person analysis)
Positive person/tested (%) 7/47 (14.9) 11/44 (25.0) 0 0.23e
Saliva (per sample analysis)d
Positive sample/tested (%) 40/5,640 (0.7) 70/5,280 (1.3) 0 <0.01e
HHV-8 DNA saliva detection among HHV-8-seropositive
patients only
N = 24 N = 28 N = 12
Per person analysis
Positive individual/tested (%) 7/24 (29.2) 11/28 (39.3) 0 0.71e
Per sample analysisd
Positive sample/tested (%) 40/2,880 (1.4) 70/3,360 (2.1) 0 0.04e
Positive samples among shedders samples (%) 40/840 (4.8) 70/1,320 (5.3) 0 0.58e
HHV-8 DNA log10 copies/mL 2.8 (2.4–3.2) 3.7 (3.3–4.5) 0 <0.01
e
Continuous variables are presented as medians and interquartile ranges; P-values are presented for comparison across three groups
aMale HIV-negative group was significantly different from male HIV-positive and female HIV-positive groups in pairwise comparison; difference between
male HIV positive-and female HIV-positive groups was not significant.
bThreshold for detection 50 copies/mL.
cIn pairwise comparison, ELISA positivity was significantly different between male HIV-positive and female HIV-positive groups only.
dPer sample analysis: six serum, six plasma, and 120 saliva samples per patient.
ePairwise comparison for male HIV-negative and male HIV-positive groups.
HHV-8, human herpesvirus 8; HIV, human immunodeficiency virus; PVL, plasma viral load; ELISA, enzyme-linked immunosorbent assay; IFA, immuno-
fluorescence assays.
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oral shedding was sporadic for all 18 shedding indi-
viduals, with shedding days ranging from 2.5% to
17% and very few shedding episodes occurring on
consecutive days.
The present findings differ from other studies that
have reported a high frequency (32–68%) of HHV-8
shedding and high viral loads among HIV-seropositive
women in Africa [3,4]. These studies were carried out
in KS endemic areas (Kenya) among very specific
populations (sex workers who did not use HAART)
[3,4]. The small number of HHV-8-seropositive
women in the present study, the different participant
characteristics, and the fact that Brazilian patients
were immunologically well controlled on HAART
may explain these different results. However, it should
be considered that some studies on gender susceptibil-
ity to HHV-8 and KS report that women are more
resistant than men to infection by HHV-8 and devel-
opment of the disease, which suggests that female
hormones may provide protection to women [15,16].
Few studies have systematically analyzed the fre-
quency and dynamics of HHV-8 oral shedding in KS
non-endemic areas [2,5–7,17,18]. In the United States,
Pauk et al. analyzed 1,134 oropharyngeal samples
obtained from daily oral collection among 23 HHV-8-
seropositive MSM (including 14 HIV-seropositive
men) for a period of approximately 50 days. They
found oral HHV-8 DNA detected at least once for 13
participants (57%), with about 50% of thosemen having
frequent shedding (defined as ≥35% positive samples)
[2]. Another study from the same group showed fre-
quent and intermittent HHV-8 oral detection: 44 MSM
collected oropharyngeal samples for periods of between
25 and 135 days, and 27 (61%) showed at least one
positive sample. However, the authors also described
HHV-8 oral shedding as intermittent and sporadic [6].
A recent study compared HHV-8 oral shedding
between diferent populations (United States, Peru,
Cameroon, Uganda, and Kenya), and the authors did
not find a regular pattern of HHV-8 oral shedding, with
a great variability observed between participants [17].
The present study found a high prevalence of
HHV-8 antibodies in all three groups, although this
varied according to the assay used (ranging from
18.7% with IFA-lytic to 56.8% for ELISA). The lack
of a gold standard for the serological diagnosis of
HHV-8 remains an obstacle for comparing the sensi-
tivity and specificity of each assay, making it difficult
to establish what is the most reliable assay to discri-
minate true HHV-8 infected individuals from those
who are not infected [14]. By testing six sequential
serum samples blindly from each patient, the present
study was able to show excellent intra-assay concor-
dance for all three techniques. Taking into account all
738 samples from the 123 individuals participating in
the study, the intra-assay concordance was ≥99% for
all assays.
One objective of this study was to determine the
performance of serological assays to identify HHV-8
oral shedders. The HHV-8 whole-virus ELISA assay
had the highest sensitivity, confirming previous
reports [9,11,14], a moderate specificity, and a high
NPV. The combination with IFA-LANA assay
increased specificity without losing much on sensitiv-
ity and had the highest PPV to detect shedders.
It was found that none of the 738 blood samples,
including those from the 18 oral shedders, were posi-
tive for HHV-8 DNA, despite triplicate testing, con-
firming earlier findings that in KS non-endemic
areas, HHV-8 detection in peripheral blood is very
rare, even among HHV-8-seropositive individuals
such as blood-bank donors [10,11]. Blood donation
by MSM has raised concerns about the possibility of
HHV-8 transmission, and in some settings, it has
been proposed to impose a lifetime donation deferral
for this group [12]. This recommendation would not
be supported by the present findings, at least for
HHV-8.
Table 2. Intra-assay concordance for six serum samples obtained from 123 patients patients in Sao Paulo, Brazil.
Assay
Overall concordance,
% (n/N)
Concordance among positive
results, % (n/N)
Concordance among negative
results, % (n/N)
Kappa (95% CI) for
overall p-Value
ELISA 100% (738/738) 100% (288/288) 100% (450/450) 100% <0.0001
IF-LANA 99.2% (732/738) 96.9% (192/198) 100% (540/540) 96% <0.0001
IF-lytic 98.9% (730/738) 94.2% (130/138) 100% (600/600) 94% <0.0001
Table 3. Performance of serological assays for the detection of salivary HHV-8 DNA shedders among 91 men (47 HIV-
seropositive and 44 HIV-seronegative MSM).
Serologic assay
Positivity, n
(%)
Sensitivity %
(95% CI)
Specificity %
(95% CI)
Positive predictive value %
(95% CI)
Negative predictive value %
(95% CI)
ELISA 18 (100.0) 100.0 (81.5–100.0) 67.1 (55.1–77.7) 42.9 (27.7–59.0) 100.0 (92.7–100.0)
IFA LANA 15 (83.3) 83.3 (58.6–96.4) 83.6 (73.0–91.2) 55.6 (35.3–74.5) 95.3 (86.9–99.0)
IFA-lytic 6 (33.3) 33.3 (13.3–59.0) 83.6 (73.0–91.2) 33.3 (13.3–59.0) 83.6 (73.0–91.2)
ELISA + IFA-LANA 15 (83.3) 83.3 (58.6–96.4) 91.8 (83.0–96.9) 71.4 (47.8–88.7) 95.7 (88.0–99.1)
ELISA + IFA-lytic 6 (33.3) 33.3 (13.3–59.0) 93.2 (84.7–97.7) 54.5 (23.4–83.3) 85.0 (75.3–92.0)
ELISA + IFA-LANA + IFA-lytic 6 (33.3) 33.3 (13.3–59.0) 98.6 (92.6–100.0) 85.7 (42.1–99.6) 85.7 (76.4–92.4)
IFA-LANA + IFA-lytic 6 (33.3) 33.3 (13.3–59.0) 94.5 (86.6–98.5) 60.0 (26.2–87.8) 85.2 (75.6–92.1)
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In conclusion, in immunologically controlled
populations of Brazil, HHV-8 oral shedding was lim-
ited to HHV-8-seropositive men, occurred infre-
quently and intermittently, and was not linked to
HHV-8 viremia, suggesting a limited potential for
oral or blood transmission.
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